Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT04861467 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

155

Enrollment

OTHER

Sponsor class

Conditions

HNSCC

Interventions

DRUG: Camrelizumab

Sponsor

Chinese Academy of Medical Sciences